ELAN
Elanco Animal Health IncorporatedMarquee-fund ownership over time
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Maverick Capital re-entered | Q1 2021 | 22Q | $30 | $20 | -34% |
| Bridgewater Associates re-entered | Q1 2023 | 13Q | $13 | $20 | +53% |
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $14 | $20 | +42% |
| D.E. Shaw | Q3 2024(8Q snapshot) | 7Q | $14 | $20 | +42% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $14 | $20 | +42% |
| Millennium Management re-entered | Q3 2024(8Q snapshot) | 7Q | $14 | $20 | +42% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Point72 Asset Management 2× in & out | Q3 2025 | Q1 2026 | → $25 | +38% |
| Renaissance Technologies | Q3 2024 | Q3 2025 | → $18 | +37% |
| Two Sigma Investments | Q3 2024 | Q2 2025 | → $13 | -8% |
| Duquesne Family Office | Q1 2021 | Q2 2021 | → $35 | +15% |
| Glenview Capital | Q1 2020 | Q2 2020 | → $19 | -38% |
| Coatue Management | Q4 2018 | Q1 2019 | → $29 | -14% |
| Viking Global Investors | Q4 2018 | Q1 2019 | → $29 | -14% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Elanco Animal Health Inc. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 2, 2026 — the most recent Form 4 on file — not from today.
- Form 40001724169-26-000025Jun 2, 2026
- Form 40001916473-26-000026Jun 2, 2026
- Form 40001479079-26-000027Jun 2, 2026
- Form 40001297000-26-000003May 26, 2026
- Form 40001352090-26-000003May 26, 2026
- Form 40001517740-26-000003May 26, 2026
- Form 40001374175-26-000002May 26, 2026
- Form 40001448579-26-000002May 26, 2026
- Form 40001186033-26-000002May 26, 2026
- Form 40001566340-26-000002May 26, 2026
- Form 40001679166-26-000006May 26, 2026
- Form 40001872431-26-000002May 26, 2026
- Form 40001183585-26-000002May 26, 2026
- Form 40001916473-26-000024May 19, 2026
- Form 40001479079-26-000025May 19, 2026
Fundamentals
XBRL · Elanco Animal Health IncorporatedAnnual figures sourced directly from Elanco Animal Health Incorporated's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Elanco Animal Health Inc — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KFORM 8-KMay 27, 2026
- 10-Q10-Q FOR THE PERIOD ENDED MARCH 31, 2026May 6, 2026
- 8-K8-K DATED MAY 6, 2026May 6, 2026
- DEF 14AProxy statementApr 8, 2026
- 10-K10-K FOR THE YEAR ENDED DECEMBER 31, 2025Feb 24, 2026
- 8-K8-K DATED FEBRUARY 24, 2026Feb 24, 2026
- 8-KFORM 8-KJan 12, 2026
- 8-KFORM 8-KDec 9, 2025
- 10-Q10-Q FOR THE PERIOD ENDED SEPTEMBER 30, 2025Nov 5, 2025
- 8-K8-K DATED NOVEMBER 5, 2025Nov 5, 2025
- 8-KFORM 8-KNov 3, 2025
- 10-QQuarterly reportAug 7, 2025
- 8-KMaterial eventAug 7, 2025
- 8-KFORM 8-KJun 26, 2025
- 8-KFORM 8-KMay 28, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Bridgewater Associates | Q1 2026 | open | $25 | $23 | -8% |
| Maverick Capital | Q4 2025 | open | $21 | $23 | +10% |
| Millennium Management | Q3 2025 | open | $18 | $20 | +11% |
| Point72 Asset Management | Q3 2025 | Q1 2026 | $18 | $25 | +38% |
| Point72 Asset Management | Q4 2024 | Q1 2025 | $14 | $11 | -20% |
| Citadel Advisors | Q3 2024 | open | $14 | $20 | +42% |
| Two Sigma Investments | Q3 2024 | Q2 2025 | $14 | $13 | -8% |
| D.E. Shaw | Q3 2024 | open | $14 | $20 | +42% |
| AQR Capital Management | Q3 2024 | open | $14 | $20 | +42% |
| Millennium Management | Q3 2024 | Q2 2025 | $14 | $13 | -8% |
| Renaissance Technologies | Q3 2024 | Q3 2025 | $13 | $18 | +37% |
| Maverick Capital | Q2 2024 | Q3 2024 | $17 | $14 | -17% |
| Bridgewater Associates | Q1 2023 | Q2 2023 | $13 | $8.57 | -34% |
| Maverick Capital | Q4 2021 | Q2 2022 | $32 | $23 | -28% |
| Maverick Capital | Q1 2021 | Q3 2021 | $30 | $32 | +4% |
| Duquesne Family Office | Q1 2021 | Q2 2021 | $30 | $35 | +15% |
| Glenview Capital | Q1 2020 | Q2 2020 | $31 | $19 | -38% |
| Coatue Management | Q4 2018 | Q1 2019 | $34 | $29 | -14% |
| Viking Global Investors | Q4 2018 | Q1 2019 | $34 | $29 | -14% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.